![[Efficacy and safety of Padma 28 in peripheral arterial occlusive disease].](/static/images/no-image.png)
Journal article
[Efficacy and safety of Padma 28 in peripheral arterial occlusive disease].
- Melzer J Institut für Naturheilkunde, Departement Innere Medizin, Universitätsspital Zürich, Schweiz. joerg.melzer@usz.ch
- Brignoli R
- Saller R
- 2006-04-04
Published in:
- Forschende Komplementarmedizin (2006). - 2006
Arterial Occlusive Diseases
Evidence-Based Medicine
Humans
Intermittent Claudication
Medicine, Tibetan Traditional
Phytotherapy
Plant Extracts
Safety
Treatment Outcome
English
BACKGROUND
The multicompound herbal drug Padma 28 is based on a formula from Tibetan Medicine and has been used in Switzerland for over 30 years in the symptomatic treatment of circulatory disorders including intermittent claudication.
OBJECTIVE
What is the current evidence regarding the clinical efficacy and safety of this drug in patients with peripheral arterial occlusive disease(PAOD)?
MATERIALS AND METHODS
Electronic databases were searched (each from inception to fall 2005) as well as the reference lists of the relevant articles.
RESULTS
14 articles were found including 6 published studies, 1 un-published study, 6 double publications and 1 meta-analysis. Six studies analyzed maximum walking distance, 5 of these showed a significant increase. The pooled data of the meta-analysis confirmed a significant and clinically relevant increase of the maximum walking distance by more than 100 m in about 1 out of 5 patients. Serious adverse events were not related to verum, non-serious adverse events were equally frequent as under placebo.
CONCLUSIONS
The evidence available shows that the multi-target therapy with Padma 28 provides statistically significant and clinically relevant relief from PAOD-related symptoms, i.e. an increased walking distance.
The multicompound herbal drug Padma 28 is based on a formula from Tibetan Medicine and has been used in Switzerland for over 30 years in the symptomatic treatment of circulatory disorders including intermittent claudication.
OBJECTIVE
What is the current evidence regarding the clinical efficacy and safety of this drug in patients with peripheral arterial occlusive disease(PAOD)?
MATERIALS AND METHODS
Electronic databases were searched (each from inception to fall 2005) as well as the reference lists of the relevant articles.
RESULTS
14 articles were found including 6 published studies, 1 un-published study, 6 double publications and 1 meta-analysis. Six studies analyzed maximum walking distance, 5 of these showed a significant increase. The pooled data of the meta-analysis confirmed a significant and clinically relevant increase of the maximum walking distance by more than 100 m in about 1 out of 5 patients. Serious adverse events were not related to verum, non-serious adverse events were equally frequent as under placebo.
CONCLUSIONS
The evidence available shows that the multi-target therapy with Padma 28 provides statistically significant and clinically relevant relief from PAOD-related symptoms, i.e. an increased walking distance.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1159/000091087
- PMID 16582560
- Persistent URL
- https://sonar.ch/global/documents/104275
Statistics
Document views: 14
File downloads: